

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT TRAZODONE HYDROCHLORIDE TABLET OBTAINED DRUG REGISTRATION CERTIFICATE FROM CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Lee's Pharmaceutical Holdings Limited (the “**Company**” or “**Lee's Pharm**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce that on 2 December 2020, the Company has successfully obtained the drug registration certificate for Trittico[®] (trazodone hydrochloride tablets) from China's National Medical Products Administration for the treatment of depression. Trazodone hydrochloride tablet is manufactured by the Italian company Angelini Pharma.

ABOUT TRAZODONE

Trazodone, a potent postsynaptic serotonin 5-HT_{2A} receptor antagonist and a moderate inhibitor of serotonin reuptake, is the original member of the SARIs (serotonin-2 antagonist/reuptake inhibitors) group of antidepressants and currently Trazodone is the only SARI marketed all around the world. The targeted indication is depression with or without anxiety. According to more than 30 years of clinical practice since the launch of the prolonged-release form, the best patient profile for Trazodone is a depressed patient with sleep disorders (80% of people suffering with depression). Trittico[®] is a prolonged-release formulation developed by Angelini Pharma with better patient compliance than any immediate release formulation of the molecule. Trazodone has been widely prescribed since its original launch in 1990's by its originator Angelini Pharma. Trittico[®] is commercialised in more than 40 countries and it is also currently a key molecule for the therapy of depressed patients with sleep disorders.

* For identification purposes only

ABOUT ANGELINI PHARMA

Angelini Pharma is the pharmaceutical division of Angelini Holding. Angelini Holding was founded in Italy at the beginning of the 20th century – almost 100 years ago – over the years it has grown into a leading international group in healthcare. Angelini Pharma today pledges in the fields of mental health (including pain), rare diseases and consumer, with highly successful over-the-counter (OTC) brands in Italy and abroad. Angelini Pharma is an integrated pharmaceutical company with extensive and well-recognised R&D programmes, in addition to world-class production facilities and international marketing activities of key compounds and leading drugs in many sectors. Strategic partnerships with international companies complete and expand the geographical areas where it operates. Angelini Pharma products are marketed in about 70 countries. It operates directly in 15 countries, employing more than 2,700 people and commercialises its products in more than 50 countries through strategic alliances with leading international pharmaceutical groups.

ABOUT LEE'S PHARM

Lee's Pharm is a research-driven and market-oriented biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with over 20 international companies and currently markets 23 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics and urology, and has more than 40 products under different development stages stemming from both internal research and development as well as from the licensing and development, commercialisation, and manufacturing rights from various United States, European and Japanese companies. Lee's Pharm has also involved in the business in ophthalmology through its investment in an associated company, Zhaoke Ophthalmology Limited.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 11 December 2020

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive Directors, Mr. Simon Miles Ball is a non-executive Director, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.